MiR-195 Suppresses the Metastasis and Epithelial-mesenchymal Transition of Hepatocellular Carcinoma by Inhibiting YAP

Overview

Journal Oncotarget

Specialty Oncology

Date 2017 Dec 17

PMID 29245938

Citations 29

Authors

Shuo Yu

Li Jing

Xiao-Ran Yin

Min-Cong Wang

Yi-Meng Chen

Ya Guo

Ke-Jun Nan

Li-Li Han

Affiliations

Soon will be listed here.

Abstract

MiR-195, a novel cancer-related microRNA, was previously reported to play an important role in many malignancies. This study aimed to investigate the role of miR-195 mediated epithelial-mesenchymal transition (EMT) and the progression of hepatocellular carcinoma (HCC) as well as the underlying mechanisms. Our result demonstrated that miR-195 were significantly down regulated in HCC and its decreased expression is associated with poor clinical features of HCC patients. Oppositely, expression level of YAP was significantly higher in HCC tissues, and the level of YAP in metastatic tissues was significantly higher. We also found that a strong inversely association between low level expression of miR-195 and high level of YAP in HCC tissues. Notably, this study confirmed that miR-195, YAP and their combination were valuable predictors for the prognosis of HCC patients. We also explored that miR-195 inhibits HCC growth and metastatic capacity. Mechanistically, we confirm that miR-195 inhibits the migration, invasion and EMT of HCC cells by suppressing YAP. Lastly, we revealed YAP was not only the downstream of miR-195 in HCC, but also mediated the promoting effects of miR-195 on the metastasis and EMT of HCC cells. Taken together, miR-195 inhibits the metastasis and EMT in HCC by targeting YAP. MiR-195/YAP pathway may potentially act as novel biomarker and attractive therapeutic target in HCC.

Citing Articles

Comprehensive review of LncRNA-mediated therapeutic resistance in non-small cell lung cancer.

Ge X, Shen Z, Yin Y Cancer Cell Int. 2024; 24(1):369.

PMID: 39522033 PMC: 11549762. DOI: 10.1186/s12935-024-03549-1.

Hazel Leaf Polyphenol Extract Alleviated Cisplatin-Induced Acute Kidney Injury by Reducing Ferroptosis through Inhibiting Hippo Signaling.

Sun M, Chang H, Jiang F, Zhang W, Yang Q, Wang X Molecules. 2024; 29(8).

PMID: 38675549 PMC: 11051766. DOI: 10.3390/molecules29081729.

Hsa-miR-194-5p and hsa-miR-195-5p are down-regulated expressed in high dysplasia HPV-positive Pap smear samples compared to normal cytology HPV-positive Pap smear samples.

Dehghani A, Khajepour F, Dehghani M, Razmara E, Zangouey M, Fekri Soofi Abadi M BMC Infect Dis. 2024; 24(1):182.

PMID: 38342922 PMC: 10860252. DOI: 10.1186/s12879-023-08942-1.

Tumor Microenvironment Remodeling in Gastrointestinal Cancer: Role of miRNAs as Biomarkers of Tumor Invasion.

Lucarini V, Nardozi D, Angiolini V, Benvenuto M, Focaccetti C, Carrano R Biomedicines. 2023; 11(6).

PMID: 37371856 PMC: 10296425. DOI: 10.3390/biomedicines11061761.

Placental stem cells-derived exosomes stimulate cutaneous wound regeneration engrailed-1 inhibition.

Zhang Y, Shi L, Li X, Liu Y, Zhang G, Wang Y Front Bioeng Biotechnol. 2022; 10:1044773.

PMID: 36568306 PMC: 9780460. DOI: 10.3389/fbioe.2022.1044773.

References

Li X, Yang W, Lou L, Chen Y, Wu S, Ding G . microRNA: a promising diagnostic biomarker and therapeutic target for hepatocellular carcinoma. Dig Dis Sci. 2014; 59(6):1099-107. DOI: 10.1007/s10620-013-3006-1. View

Fite K, Gomez-Cambronero J . Down-regulation of MicroRNAs (MiRs) 203, 887, 3619 and 182 Prevents Vimentin-triggered, Phospholipase D (PLD)-mediated Cancer Cell Invasion. J Biol Chem. 2015; 291(2):719-30. PMC: 4705392. DOI: 10.1074/jbc.M115.686006. View

Dykxhoorn D . MicroRNAs and metastasis: little RNAs go a long way. Cancer Res. 2010; 70(16):6401-6. PMC: 2922433. DOI: 10.1158/0008-5472.CAN-10-1346. View

Liu C, Guan H, Wang Y, Chen M, Xu B, Zhang L . miR-195 Inhibits EMT by Targeting FGF2 in Prostate Cancer Cells. PLoS One. 2015; 10(12):e0144073. PMC: 4674136. DOI: 10.1371/journal.pone.0144073. View

Zhang X, Liu X, Luo J, Xiao W, Ye X, Chen M . Notch3 inhibits epithelial-mesenchymal transition by activating Kibra-mediated Hippo/YAP signaling in breast cancer epithelial cells. Oncogenesis. 2016; 5(11):e269. PMC: 5141289. DOI: 10.1038/oncsis.2016.67. View

Zimmerman A, Wu S . MicroRNAs, cancer and cancer stem cells. Cancer Lett. 2010; 300(1):10-9. PMC: 2991536. DOI: 10.1016/j.canlet.2010.09.019. View

Yimlamai D, Fowl B, Camargo F . Emerging evidence on the role of the Hippo/YAP pathway in liver physiology and cancer. J Hepatol. 2015; 63(6):1491-501. PMC: 4654680. DOI: 10.1016/j.jhep.2015.07.008. View

Finn R . Current and Future Treatment Strategies for Patients with Advanced Hepatocellular Carcinoma: Role of mTOR Inhibition. Liver Cancer. 2013; 1(3-4):247-56. PMC: 3760459. DOI: 10.1159/000343839. View

Kalluri R, Weinberg R . The basics of epithelial-mesenchymal transition. J Clin Invest. 2009; 119(6):1420-8. PMC: 2689101. DOI: 10.1172/JCI39104. View

10.

Huang S, He X . The role of microRNAs in liver cancer progression. Br J Cancer. 2010; 104(2):235-40. PMC: 3031886. DOI: 10.1038/sj.bjc.6606010. View

11.

Gong F, Ren P, Zhang Y, Jiang J, Zhang H . MicroRNAs-491-5p suppresses cell proliferation and invasion by inhibiting IGF2BP1 in non-small cell lung cancer. Am J Transl Res. 2016; 8(2):485-95. PMC: 4846898. View

12.

Zhu A, Duda D, Sahani D, Jain R . HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol. 2011; 8(5):292-301. PMC: 3266719. DOI: 10.1038/nrclinonc.2011.30. View

13.

Salvi A, Abeni E, Portolani N, Barlati S, de Petro G . Human hepatocellular carcinoma cell-specific miRNAs reveal the differential expression of miR-24 and miR-27a in cirrhotic/non-cirrhotic HCC. Int J Oncol. 2012; 42(2):391-402. PMC: 3583619. DOI: 10.3892/ijo.2012.1716. View

14.

Xu R, Zheng L, He D, Meng J, Xia L, Hao X . Retraction Note to: Profiling of differentially expressed microRNAs (miRNAs) during differentiation of rat hepatic oval cells (HOCs) into hepatocellular carcinoma (HCC) cells. Clin Transl Oncol. 2015; 17(11):935. DOI: 10.1007/s12094-015-1386-8. View

15.

Zhang L, Yang S, Chen X, Stauffer S, Yu F, Lele S . The hippo pathway effector YAP regulates motility, invasion, and castration-resistant growth of prostate cancer cells. Mol Cell Biol. 2015; 35(8):1350-62. PMC: 4372700. DOI: 10.1128/MCB.00102-15. View

16.

Moroishi T, Hansen C, Guan K . The emerging roles of YAP and TAZ in cancer. Nat Rev Cancer. 2015; 15(2):73-79. PMC: 4562315. DOI: 10.1038/nrc3876. View

17.

Wang M, Zhang J, Tong L, Ma X, Qiu X . MiR-195 is a key negative regulator of hepatocellular carcinoma metastasis by targeting FGF2 and VEGFA. Int J Clin Exp Pathol. 2016; 8(11):14110-20. PMC: 4713510. View

18.

Yuan Y, Li D, Li H, Wang L, Tian G, Dong Y . YAP overexpression promotes the epithelial-mesenchymal transition and chemoresistance in pancreatic cancer cells. Mol Med Rep. 2015; 13(1):237-42. DOI: 10.3892/mmr.2015.4550. View

19.

Mirzaei H, Sahebkar A, Mohammadi M, Yari R, Salehi H, Jafari M . Circulating microRNAs in Hepatocellular Carcinoma: Potential Diagnostic and Prognostic Biomarkers. Curr Pharm Des. 2016; 22(34):5257-5269. DOI: 10.2174/1381612822666160303110838. View

20.

Li N, Yu N, Wang J, Xi H, Lu W, Xu H . miR-222/VGLL4/YAP-TEAD1 regulatory loop promotes proliferation and invasion of gastric cancer cells. Am J Cancer Res. 2015; 5(3):1158-68. PMC: 4449443. View